Kathy Ngo

Prior to joining the pharmaceutical industry, Kathy Ngo spent over 10 years in academia focused on understanding how cells communicate with one another during development. At the University of California, Los Angeles, Dr. Ngo uncovered a novel mechanism by which phospholipids can activate non-canonical Hedgehog signaling, and identified Notch signaling as a major determinant for a transient population of symmetrically dividing retinal stem cells that had not been previously identified. While at Aridis Pharmaceuticals, Dr. Ngo played a key role in the development of a CRISPR-based technology to enhance antibody production, and the development of a microfluidics-based HTS platform for rapid, single-cell clonal selection of CHO cells for monoclonal antibody production. Dr. Ngo holds Bachelor’s and Doctorate degrees from UCLA. She has co-authored over 15 research papers, reviews, and patents.